CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy
- 31 January 2007
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 104 (1) , 176-180
- https://doi.org/10.1016/j.ygyno.2006.07.027
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Performance Characteristics of Seven Automated CA 125 AssaysAmerican Journal of Clinical Pathology, 2006
- Pretreatment CA-125 and Risk of Relapse in Advanced Ovarian CancerJournal of Clinical Oncology, 2006
- Consolidation for Ovarian Cancer in RemissionJournal of Clinical Oncology, 2006
- Intraperitoneal Cisplatin and Paclitaxel in Ovarian CancerNew England Journal of Medicine, 2006
- Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary?Annals of Oncology, 2005
- Cancer Statistics, 2005CA: A Cancer Journal for Clinicians, 2005
- Intraperitoneal Chemotherapy for Ovarian Carcinoma: Results of Long-Term Follow-UpJournal of Clinical Oncology, 2002
- Isolation and characterization of ovarian cancer antigen CA 125 using a new monoclonal antibody (VK-8): identification as a mucin-type moleculeInternational Journal of Cancer, 1997
- A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian CancerNew England Journal of Medicine, 1983
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958